For research use only
| Cat No. | ABC-X0243C |
| Product Type | Overexpression Stable Cell Lines |
| Cell Type | Epithelial-like |
| Species | Human |
| Host Cell | MC38 |
| Source Organ | Colon |
| Disease | Colon Adenocarcinoma |
| Storage | Liquid Nitrogen |
MC38 cell line stably overexpressing PVRL4, ideal for cell adhesion, tumor progression studies, and immuno-oncology drug development applications.
Xpress™ Human PVRL4 Overexpression Cell Line (MC38) is a genetically engineered model derived from murine colon adenocarcinoma MC38 cells based on customers’ requirement. PVRL4 MC38 overexpression cell line is generated by stable integration of exogenous human PVRL4 into MC38 host cells using our optimized transduction of lentiviral vectors. Overexpression clone is validated at gene level by qRT-PCR.
Target
PVRL4, also known as nectin-4, is a member of the immunoglobulin superfamily involved in cell-cell adhesion, particularly within epithelial tissues. It plays a crucial role in tumor proliferation and metastasis and has been identified as a therapeutic target in multiple cancers including breast and lung cancers. The protein is predominantly localized at adherens junctions.
AcceGen offers generation of stable overexpression cell lines targeting any gene of your interest. Polyclonal or monoclonal is optional based on customers’ research needs.
| Species | Human |
| Cat.No | ABC-X0243C |
| Product Category | Transfected Stable Cell Lines |
| Size/Quantity | 1 vial |
| Cell Type | Epithelial-like |
| Growth Mode | Adherent |
| Shipping Info | Dry Ice |
| Growth Conditions | 37 °C, 5% CO2 |
| Source Organ | Colon |
| Disease | Colon Adenocarcinoma |
| Biosafety Level | 1 |
| Storage | Liquid Nitrogen |
| Product Type | Overexpression Stable Cell Lines |
| Host Cell | MC38 |
| Quality Control | All cells test negative for mycoplasma, bacteria, yeast, and fungi. |
The PVRL4 MC38 Overexpression Cell Line serves as a reliable model for investigating nectin-4-mediated tumorigenesis and therapeutic interventions. It is particularly useful for antibody-based therapy screening, including development of nectin-4 targeting agents and immunotherapies such as enfortumab vedotin.